Search results for "Systemic."

showing 10 items of 756 documents

Histopathology of the gut in rheumatic diseases

2018

The gastrointestinal tract regulates the trafficking of macromolecules between the environment and the host through an epithelial barrier mechanism and is an important part of the immune system controlling the equilibrium between tolerance and immunity to non-self-antigens. Various evidence indicates that intestinal inflammation occurs in patients with rheumatic diseases. In many rheumatic diseases intestinal inflammation appears to be linked to dysbiosis and possibly represents the common denominator in the pathogenesis of different rheumatic diseases. The continuative interaction between dysbiosis and the intestinal immune system may lead to the aberrant activation of immune cells that ca…

Arthritislcsh:MedicineIntestinal inflammationPathogenesisSystemic sclerosiBehçet’s diseaseIntestinal MucosaConnective Tissue DiseasesGastrointestinal tractBehcet SyndromeIntestineIntestinesSymbiosimedicine.symptomHumanAnkylosing spondylitislcsh:Internal medicineInflammationSystemic lupus erythematosuRheumatic DiseaseImmune systemSystemic lupus erythematosusRheumatologyImmunityRheumatic DiseasesSpondylarthritismedicineHumansSpondylitis AnkylosingRheumatoid arthritisSymbiosislcsh:RC31-1245Rheumatoid arthritiConnective Tissue DiseaseInflammationAnkylosing spondylitisbusiness.industryArthritis PsoriaticSpondylarthritilcsh:RMuscle Smoothmedicine.diseaseBehget’s diseaseDysbiosiAnkylosing spondylitiSettore MED/16 - ReumatologiaImmunologyDysbiosisbusinessDysbiosisReumatismo
researchProduct

Safer chemicals using less animals: kick-off of the European ONTOX project

2021

The 3Rs concept, calling for replacement, reduction and refinement of animal experimentation, is receiving increasing attention around the world, and has found its way to legislation, in particular in the European Union. This is aligned by continuing high-level efforts of the European Commission to support development and implementation of 3Rs methods. In this respect, the European project called "ONTOX: ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment" was recently initiated with the goal to provide a functional and sustainable solution for advancing human risk assessment of chemicals without the use of animal…

Artificial intelligenceComputer science010501 environmental sciencesOntology (information science)In Vitro TechniquesAnimal Testing AlternativesToxicology01 natural sciencesRisk Assessment3Rs03 medical and health sciencesIn vitroSAFERAdverse Outcome PathwayToxicity TestsEuropean projectmedia_common.cataloged_instanceAnimalsHumansComputer SimulationEuropean UnionAnimal testingEuropean union0105 earth and related environmental sciencesExposure assessmentmedia_common0303 health sciencesOntologyIn silico030311 toxicology3. Good healthVariety (cybernetics)Gene OntologyRisk analysis (engineering)Systemic toxicityONTOXRisk assessment
researchProduct

Neurogenic pulmonary oedema after generalized epileptic seizure

1998

The diagnosis 'tonic clonic seizure' is frequently established by emergency physicians on scene. In patients with epilepsy mortality due to accidents, asphyxia, cardiac arrhythmias or postictal neurogenic pulmonary oedema (NPO) is twice as high as in the general population. We report a case of acute pulmonary oedema after a tonic clonic seizure. Following this event, the patient developed respiratory insufficiency and evidence of pulmonary oedema not associated with the classic aetiologies of congestive heart failure, aspiration or toxic exposure. The patient survived the incident after aggressive prehospital treatment, long-term intensive care and subsequent rehabilitation. A systematic ca…

Asphyxiaeducation.field_of_studybusiness.industryPopulationmedicine.diseaseSystemic inflammatory response syndromeEpilepsyAnesthesiaIntensive careHeart failureEmergency MedicineMedicineEpileptic seizuremedicine.symptombusinesseducationIntracranial pressureEuropean Journal of Emergency Medicine
researchProduct

Internal Simulation of an Agent’s Intentions

2013

We present the Associative Self-Organizing Map (A-SOM) and propose that it could be used to predict an agent’s intentions by internally simulating the behaviour likely to follow initial movements. The A-SOM is a neural network that develops a representation of its input space without supervision, while simultaneously learning to associate its activity with an arbitrary number of additional (possibly delayed) inputs. We argue that the A-SOM would be suitable for the prediction of the likely continuation of the perceived behaviour of an agent by learning to associate activity patterns over time, and thus a way to read its intentions.

Associative Self-Organizing Map; Internal Simulation;ContinuationArtificial neural networkbusiness.industryComputer scienceAssociative Self-Organizing MapRepresentation (systemics)Artificial intelligenceSpace (commercial competition)businessInternal SimulationAssociative property
researchProduct

Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors

2022

Background: The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular carcinoma not amenable to locoregional treatments, be-coming the standard of care of systemic therapy.Aim: This study aimed at assessing real-world feasibility of atezolizumab-bevacizumab in patients treated with tyrosine-kinase inhibitors.Methods: Among 1447 patients treated with tyrosine-kinase inhibitors from January 2010 to December 2020, we assessed the percentage of those potentially eligible to atezolizumab-bevacizumab (according to IMbrave-150 trial criteria), and the overall survival of eligible and non-eligible patients.Results: 422 (…

Atezolizumab-bevacizumabClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolCarcinoma HepatocellularSystemic therapyHepatologyHepatocellular carcinomaTirosin-kinase inhibitorLiver NeoplasmsGastroenterologyTirosin-kinase inhibitor.Atezolizumab-bevacizumab; Hepatocellular carcinoma; Systemic therapy; Tirosin-kinase inhibitorBevacizumabFeasibility StudieTyrosineHumanDigestive and Liver Disease
researchProduct

Genetics and novel aspects of therapies in systemic lupus erythematosus.

2015

Autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, autoimmune hepatitis and inflammatory bowel disease, have complex pathogeneses and the factors which cause these disorders are not well understood. But all have in common that they arise from a dysfunction of the immune system, interpreting self components as foreign antigens. Systemic lupus erythematosus (SLE) is one of these complex inflammatory disorders that mainly affects women and can lead to inflammation and severe damage of virtually any tissue and organ. Recently, the application of advanced techniques of genome-wide scanning revealed more genetic information about SLE than previously possible. These case-contro…

Autoimmune diseaseMultiple sclerosisImmunologyGenome-wide association studyAutoimmune hepatitisBiologymedicine.diseaseInflammatory bowel diseaseImmune systemAutologous stem-cell transplantationTreatment OutcomeRheumatoid arthritisHistocompatibility AntigensImmunologymedicineImmunology and AllergyAnimalsHumansLupus Erythematosus SystemicGenetic Predisposition to Diseaseskin and connective tissue diseasesImmunosuppressive AgentsGenome-Wide Association StudyAutoimmunity reviews
researchProduct

PS5:100 Patophysiological role of type i and iii interferons in systemic lupus erythematosus (sle)

2018

Systemic Lupus erythematosus (SLE) is an autoimmune disease characterised by activated autoreactive lymphocytes and autoantibodies, resulting in tissue damage in multiple organs. An important factor for the disease´s mortality is the development of Lupus nephritis (LN). Type I and III interferons, which are both part of the antiviral defense, have both been associated with the disease´s activity. In sera and urine of SLE patients an enhanced level of IL28/29 was described, but their distinct functional role in the course of disease need to be further investigated. To determine the role of type I and III interferons during onset and progression of autoimmunity – with focus on the development…

Autoimmune diseaseSystemic lupus erythematosusbusiness.industryLupus nephritisAutoantibodyGlomerulonephritisSpleenmedicine.diseasemedicine.disease_causeAutoimmunitymedicine.anatomical_structureimmune system diseasesImmunologyMedicineskin and connective tissue diseasesbusinessReceptorPoster session 5: Innate and adaptive immunity
researchProduct

Autoimmune ear disease: clinical and diagnostic relevance in Cogan’s sydrome

2017

The autoimmune inner ear disease is a clinical syndrome with uncertain pathogenesis that is often associated to rapidly progressive hearing loss that, especially at the early stages of disease, may be at monoaural localization, although more often it is at binaural localization. It usually occurs as a sudden deafness, or a rapidly progressive sensorineural hearing loss. In this study a particular form of autoimmune inner ear disease is described, Cogan’s syndrome. Cogan’s syndrome is a chronic inflammatory disorder that most commonly affects young adults. Clinical hallmarks are interstitial keratitis, vestibular and auditory dysfunction. Associations between Cogan’s syndrome and systemic va…

Autoimmune ear disordermedicine.medical_specialtyPathologyInterstitial keratitisHearing lossEar diseaseCase ReportDisease03 medical and health sciences0302 clinical medicinemedicineotorhinolaryngologic diseases030223 otorhinolaryngologyAortitis030203 arthritis & rheumatologyCogan’s syndromebusiness.industryAutoimmune inner ear diseaseHearing lossmedicine.diseaselcsh:OtorhinolaryngologyDermatologylcsh:RF1-547OtorhinolaryngologyHearing loss.Sensorineural hearing lossAutoimmune ear disorder; Cogan’s syndrome; Hearing loss.medicine.symptombusinessSystemic vasculitisAudiology Research
researchProduct

Proteomic analysis of Kveim reagent identifies targets of cellular immunity in sarcoidosis

2017

Background Kveim-reagent (Kv) skin testing was a historical method of diagnosing sarcoidosis. Intradermal injection of treated sarcoidosis spleen tissue resulted in a granuloma response at injection site by 4–6 weeks. Previous work indicates proteins as the possible trigger of this reaction. We aimed to identify Kv-specific proteins and characterise the ex vivo response of Peripheral Blood Mononuclear Cells (PBMCs) from sarcoidosis, tuberculosis and healthy control patients when stimulated with both Kv and selected Kv-specific proteins. Methods Kv extracts were separated by 1D-SDS-PAGE and 2D-DIGE and then underwent mass spectrometric analysis for protein identification. Sarcoidosis and con…

Bacterial DiseasesMaleProteomics0301 basic medicineCellular immunityPhysiologylcsh:MedicineVimentinBiochemistry0302 clinical medicineTandem Mass SpectrometryImmune PhysiologyMedicine and Health SciencesMedicinelcsh:ScienceCITRULLINATED VIMENTINInnate Immune SystemImmunity CellularMultidisciplinarybiologyMYCOBACTERIAL CATALASE-PEROXIDASEPEPTIDESMiddle Aged3. Good healthMultidisciplinary SciencesInfectious DiseasesGranulomaCytokinesScience & Technology - Other TopicsElectrophoresis Polyacrylamide GelFemaleResearch ArticleAdultSarcoidosisGeneral Science & TechnologyInflammatory DiseasesSYSTEMIC SARCOIDOSISImmunologyANTIGENTUBERCULOSISPeripheral blood mononuclear cell03 medical and health sciencesImmune systemRheumatologyAntigenMD MultidisciplinaryVimentinHumansSecretionScience & Technologybusiness.industrylcsh:RBiology and Life SciencesProteinsMolecular DevelopmentTropical Diseasesmedicine.diseaseRHEUMATOID-ARTHRITISCytoskeletal Proteins030104 developmental biology030228 respiratory systemImmune SystemImmunologybiology.proteinT-CELLSIndicators and Reagentslcsh:QCytokine secretionBODIESPhysiological ProcessesbusinessSpleenEx vivoDevelopmental BiologyRCRESPONSES
researchProduct

Nadzór makroostrożnościowy w Unii Europejskiej. Jak bardzo potrzebny? Jak bardzo skuteczny?

2014

Banking UnionESRBsystemic riskESFSmacro-prudential supervisionECB
researchProduct